Eli Lilly Faces Share Decline Amid Competition Concerns
Eli Lilly (NYSE: LLY) has seen its shares drop 15% year-to-date, raising concerns about increased competition in the weight-loss medicine market. Despite this decline, the company is witnessing growth in its gross and operating margins, attributed to its GLP-1 treatments, such as Zepbound and Mounjaro. As of the fourth quarter of 2025, Eli Lilly’s margins have surpassed those of similar-sized peers.
The pharmaceutical giant has invested $55 billion in expanding manufacturing capacity since 2020 and is leveraging artificial intelligence to enhance drug discovery and clinical trial efficiencies. However, it faces challenges, including lower realized prices for some products and the potential impact of new anti-obesity drugs entering the market.
